[1]屈桓瑋,呂松岑.全膝關節置換術后靜脈血栓栓塞的預防研究[J].醫學信息,2019,(20):49-52.[doi:10.3969/j.issn.1006-1959.2019.20.014]
 QU Huan-wei,LYU Song-Cen.Prevention of Venous Thromboembolism after Total Knee Arthroplasty[J].Medical Information,2019,(20):49-52.[doi:10.3969/j.issn.1006-1959.2019.20.014]
點擊復制

全膝關節置換術后靜脈血栓栓塞的預防研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
49-52
欄目:
綜述
出版日期:
2019-10-15

文章信息/Info

Title:
Prevention of Venous Thromboembolism after Total Knee Arthroplasty
文章編號:
1006-1959(2019)20-0049-04
作者:
屈桓瑋呂松岑
(哈爾濱醫科大學附屬第二醫院骨科,黑龍江 哈爾濱 150000)
Author(s):
QU Huan-weiLYU Song-Cen
(Department of Orthopaedics,the Second Affiliated Hospital of Harbin Medical University, Harbin 150000,Heilongjiang,China)
關鍵詞:
靜脈血栓栓塞癥預防阿司匹林全膝關節置換術
Keywords:
Venous thromboembolismPreventionAspirinTotal knee arthroplasty
分類號:
R605
DOI:
10.3969/j.issn.1006-1959.2019.20.014
文獻標志碼:
A
摘要:
靜脈血栓栓塞癥(VTE)是全膝關節置換術后發生和死亡的主要原因。研究顯示,術后發生靜脈血栓栓塞癥可延長住院時間。在過去15年中,盡管臨床上采用了全面的靜脈血栓栓塞預防方案,但全膝關節置換術后出現肺栓塞的發生率基本保持不變,約為0.4%。目前VTE預防方案包括早期下地行走、患者評估和藥物治療等。對于具有靜脈血栓栓塞癥風險的患者,阿司匹林應用越來越廣泛。最新研究證實,阿司匹林具有相對較低的出血風險和低成本效益。也有研究認為,新型口服抗凝劑、華法林、低分子肝素,包括Xa因子和直接凝血酶抑制劑均對降低術后VTE有效,但可能與出血和傷口并發癥發生率的增加有關。本文主要綜述近年來VTE預防的研究進展,旨在為臨床醫生提供用藥指導。
Abstract:
Venous thromboembolism (VTE) is the leading cause of death and death after total knee arthroplasty. Studies have shown that postoperative VTE can prolong hospital stay. In the past 15 years, despite the clinical use of a comprehensive VTE prevention program, the incidence of pulmonary embolism after total knee arthroplasty remained essentially unchanged (approximately 0.4%). Current VTE prevention programs include early ground walking, patient assessment, and medication. Aspirin is increasingly used in patients at risk for venous thromboembolism. Recent research confirms that aspirin has a relatively low risk of bleeding and low cost benefits. Studies have also suggested that new oral anticoagulants, warfarin, low molecular weight heparin, including factor Xa and direct thrombin inhibitors, are effective in reducing postoperative VTE, but may be associated with increased rates of bleeding and wound complications. This article mainly reviews the recent research on mechanical compression devices and drug VTE prevention, aiming to provide reference for clinical.

參考文獻/References:

[1]Falck-Ytter Y,Francis CW,Johanson NA,et al.Prevention of VTE in orthopedic surgery patients:antithrombotic therapy and prevention of thrombosis American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(Suppl2):e278S-e325S. [2]Mont MA,Jacobs JJ,Boggio LN,et al.AAOS Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty[J].Am Acad Orthop Surg,2014,19(12):768-776. [3]Hamilton WG,Reeves JD,Fricka KB,et al.Mechanical thromboembolic prophylaxis with risk stratification in total knee arthroplasty[J].J Bone Joint Surg,2015,30(1):43-45. [4]Cherian JJ,Jauregui JJ, Pierce TP,et al.A current review of mechanical compression in venous thromboembolic prophylaxis in total knee and total hip arthroplasty[J].Curropin Rheumatol,2016,15(212):1027-1033. [5]Perzborn E,Kubitza D,Misselwitz F.Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and reatment of thromboembolic disorders[J].Hamostaseologie,2017,27(4):282-289. [6]Parvizi J,Huang R,Raphael IJ,et al.Timing of symptomatic pulmonary embolism with warfarin following arthroplasty[J].Arthroplasty,2015,30(6):1050-1053. [7]Bala A,Huddleston JI,Goodman SB,et al.Venous thromboembolism prophylaxis after TKA: aspirin, warfarin,enoxaparin,or factor Xa inhibitors[J].Clin Orthop Relat Res,2017,475(9):2205-2213. [8]Mont MA,Jacobs JJ.AAOS clinical practice guideline:preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty[J].Am Acad Orthop Surg,2011,19(12):777-778. [9]Suen K,Westh RN,Churilov L,et al.Low-molecular-weight heparin and the relative risk of surgical site bleeding complications:results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty[J].Arthroplasty,2017,32(9):2911-2919. [10]Ricket AL,Stewart DW,Wood RC,et al.Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban or enoxaparin[J].Ann of Pharmacother,2016(50):270-275. [11]Zou Y,Tian S,Wang Y.Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty[J].Blood Coagul Fibrinolysis,2016(25):660-664. [12]Parvizi J,Huang R,Restrepo C,et al.Low-dose aspirin is effective chemoprophylaxis gainst clinically important venous thromboembolism following total joint arthroplasty:a preliminary analysis[J].Bone Joint Surg Am,2017,99(2):91-98. [13]Feldstein MJ,Low SL,Chen AF,et al.Risk factors for venous thromboembolism after total hip and knee replacement surgery[J].Curr Opin Pulm Med,2002(8):365-371. [14]Ogonda L,Hill J,Doran E,et al.Aspirin for thromboprophylaxis after primary lower limb arthroplasty:early thromboembolic events and 90 day mortality in 11,459 patients[J].Bone Joint,2016,98-B(3):341-348. [15]Kim YH,Choi IY,Park MR,et al.Prophylaxis for deep vein thrombosis with aspirin or low molecular weight dextran in Korean patients undergoing total hip replacement.A randomized controlled trial[J].Int Orthop,2018(22):6-10. [16]Huang R,Buckley PS,Scott B,et al.Administration of aspirin as a prophylaxis agent against venous thromboembolism results in lower incidence of periprosthetic joint infection[J].Arthroplasty,2015,30(9Suppl):39-41. [17]Lassen MR,Raskob GE,Gallus A,et al.Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J].N Engl J Med,2009,361(6):594-604. [18]Lassen MR,Raskob GE,Gallus A,et al.ADVANCE-2 investigators.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement(ADVANCE-2):a randomised double-blind trial[J].Lancet,2010,375(9717):807-815. [19]Kakkar AK,Brenner B,Dahl OE,et al.RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39. [20]Russell RD,Huo MH.Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty[J].Arthroplasty,2013,28(9):1477-1481. [21]Eriksson BI,Smith H,Yasothan U,et al.Dabigatran etexilate[J].Nat Rev Drug,2008,7(7):557-558. [22]Eriksson BI,Dahl OE,Rosencher N,et al.RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial[J].Thromb Haemost,2007,5(11):2178-2185. [23]Gomez D,Razmjou H,Donovan A,et al.Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery[J].Thromb Haemost,2017(8):678-683. [24]Charters MA,Frisch NB,Wessell NM,et al.Enoxaparin versus no anticoagulation prophylaxis after total knee arthroplasty in Thai patients: a randomized controlled trial[J].Med Assoc Thai,2017(100):42-49. [25]Wang JW,Chen B,Lin PC,et al.The efficacy of combined use of rivaroxaban and tranexamic acid on blood conservation in minimally invasive total knee arthroplasty a double-blind randomized, controlled trial[J].Arthroplasty,2017,32(3):801-806. [26]Garfinkel JH,Gladnick BP,Roland N,et al.Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial[J].Orthop Surg,2018(17):1-5. [27]Bloch BV,Patel V,Best AJ.Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement[J].Bone Joint,2014,96-B(1):122-126. [28]Venker BT,Ganti BR,Lin H,et al.Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty:a metaanalysis[J].Arthroplasty,2017,32(2):645-652.

相似文獻/References:

[1]梁 鋼.造影劑腎病的診治進展[J].醫學信息,2018,(04):45.[doi:10.3969/j.issn.1006-1959.2018.04.015]
 LIANG Gang.Progress in Diagnosis and Treatment of Contrast Nephropathy[J].Medical Information,2018,(20):45.[doi:10.3969/j.issn.1006-1959.2018.04.015]
[2]胡少勇,姜浩斌,張景碩,等.3例動脈瘤夾閉術后腦梗塞的手術治療報告[J].醫學信息,2018,(07):189.[doi:10.3969/j.issn.1006-1959.2018.07.068]
 HU Shao-yong,JIANG Hao-bin,ZHANG Jing-shuo,et al.Surgical Treatment of 3 Cases of Cerebral Infarction after Aneurysm Clipping[J].Medical Information,2018,(20):189.[doi:10.3969/j.issn.1006-1959.2018.07.068]
[3]徐 潔.宮頸癌篩查及預防的研究進展[J].醫學信息,2018,(09):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
 XU Jie.Advances in Screening and Prevention of Cervical Cancer[J].Medical Information,2018,(20):70.[doi:10.3969/j.issn.1006-1959.2018.09.022]
[4]曾凡劍,吳岑江.預防胰十二指腸切除術后胰漏的研究進展[J].醫學信息,2018,(16):30.[doi:10.3969/j.issn.1006-1959.2018.16.009]
 ZENG Fan-jian,WU Cen-jiang.Progress in Prevention of Pancreatic Leakage after Pancreaticoduodenectomy[J].Medical Information,2018,(20):30.[doi:10.3969/j.issn.1006-1959.2018.16.009]
[5]杜治國,何 龍,黃 進,等.下肢創傷骨折后靜脈血栓栓塞癥相關檢測項目分析[J].醫學信息,2019,(10):64.[doi:10.3969/j.issn.1006-1959.2019.10.022]
 DU Zhi-guo,HE Long,HUANG Jin,et al.Analysis of Related Items of Venous Thromboembolism after Traumatic Fracture of Lower Extremity[J].Medical Information,2019,(20):64.[doi:10.3969/j.issn.1006-1959.2019.10.022]
[6]齊尚忠,張 強.低位直腸癌前切除綜合征的發病機制及防治研究[J].醫學信息,2019,(20):37.[doi:10.3969/j.issn.1006-1959.2019.20.011]
 QI Shang-zhong,ZHANG Qiang.Pathogenesis and Prevention of Low Rectal Cancer Anterior Resection Syndrome[J].Medical Information,2019,(20):37.[doi:10.3969/j.issn.1006-1959.2019.20.011]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图